OncoMatch/Clinical Trials/NCT06789848
Ligufalimab and Cadonilimab in Advanced Liver Cancers
Is NCT06789848 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Ligufalimab and Cadonilimab for advanced hepatocellular carcinoma.
Treatment: Ligufalimab · Cadonilimab — The goal of this clinical trial is to find out if the combination of Ligufalimab and Cadonilimab are effective in treating advanced hepatobiliary cancers that have failed prior therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Cholangiocarcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1/PD-L1 therapy
Refractory to or relapsed after prior anti-PD-1/L1 antibody therapy. May have received anti-PD-1/L1 monotherapy or combination therapy as any line of therapy including in the neoadjuvant or adjuvant setting.
Cannot have received: immune checkpoint inhibitor
Exception: Patients who discontinued prior immune checkpoint inhibitor treatment due to a high-grade toxicity (Grade 4) are not eligible.
Patients who discontinued prior immune checkpoint inhibitor treatment due to a high-grade toxicity (Grade 4) are not eligible.
Cannot have received: immune checkpoint inhibitor
Exception: Patients who discontinued prior immune checkpoint inhibitor treatment due to Grade ≥ 3 or Grade 2 serious toxicity (i.e., pneumonitis, uveitis, neurological symptoms, cardiac toxicity, etc.) immune-related adverse events.
Patients who discontinued prior immune checkpoint inhibitor treatment due to Grade ≥ 3 or Grade 2 serious toxicity (i.e., pneumonitis, uveitis, neurological symptoms, cardiac toxicity, etc.) immune-related adverse events.
Lab requirements
Blood counts
Platelet count ≥ 50,000/mm3; Hgb ≥ 9 g/dl; Absolute neutrophil ≥ 1,000 cells/mm3; INR ≤ 2
Kidney function
Calculated creatinine clearance (CrCl) ≥ 40 mL/min
Liver function
Total bilirubin ≤ 3 mg/ml (exceptions for Gilbert's syndrome or distal malignant obstruction); AST, ALT ≤ 5 times ULN; Albumin ≥ 2.0 g/dl; Child-Pugh Score A or B7 (only applicable for Cohort A)
Adequate organ and marrow function (without chronic, ongoing growth factor support or transfusion in the last 2 weeks) as defined below: Platelet count ≥ 50,000/mm3; Hgb ≥ 9 g/dl; Absolute neutrophil ≥ 1,000 cells/mm3; Total bilirubin ≤ 3 mg/ml (exceptions for Gilbert's syndrome or distal malignant obstruction); INR ≤ 2; AST, ALT ≤ 5 times ULN; Calculated creatinine clearance (CrCl) ≥ 40 mL/min; Albumin ≥ 2.0 g/dl; Child-Pugh Score A or B7 (only applicable for Cohort A)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Texas Southwestern Medical Center · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify